Background and objective: Studies from epidemiology suggest that ambient temperature is one of the underlying triggers and potential causes of asthma. The aim of this study was to examine the impact and the molecular mechanism of temperature-invoked airway inflammation using an experimental model of asthma in BALB/c mice. Methods: Mice were exposed to different temperature conditions (steady 26 C, 26 C/18 C cycle, 26 C/10 C cycle) and received sensitization and challenge of ovalbumin (OVA) during a 21-day period. HC030031, a selective transient receptor potential A1 (TRPA1) channel blocker, was used to investigate the underlying mechanism of TRPA1 in 'asthmatic' airways. After the final OVA challenge, in vivo lung function was measured, and bronchoalveolar lavage fluid (BALF) and pulmonary inflammation were assessed. Results: The temperature variations, especially the largest temperature difference (16 C), exacerbated airway inflammation in OVA-induced mice, increasing the levels of serum total-IgE (immunoglobulin E) and IgG1, inflammatory cells and cytokines in BALF. Analysis of histopathological changes and lung function verified that repeated exposure to very cold and changed temperatures aggravated airway hyperresponsiveness (AHR). Significant upregulation of TRPA1 expression was revealed by immunohistochemistry in the presence of the largest temperature variation (26 C/10 C cycle), while administration of HC030031 successfully inhibited TRPA1 expression, thus attenuating the asthma-like pathological features. Conclusion: Repeated exposure to temperature variation exacerbated experimental 'asthma' and TRPA1 mediated this temperature-dependent inflammatory effect.
INTRODUCTION
People in everyday life frequently experience temperature variations as a result of diurnal temperature changes or the use of indoor heating and cooling devices. Such temperature stimuli are believed to increase the incidence of temperature-related diseases 1,2 and increase respiratory symptoms among a sensitive subpopulation. 3, 4 It is, therefore, of importance to understand the underlying mechanism to improve both individual and population health.
Asthma has dramatically increased in incidence over the last decade, currently affecting 235 million people worldwide. [5] [6] [7] According to epidemiological surveys, a cold environmental stimulus is believed a 'trigger' exacerbating existing asthma symptoms, 8 or may directly trigger asthma. 9 Hyrkäs et al. 10 surveyed 1623 young subjects and found that existing asthma increased the risks of all cold-weather related respiratory symptoms. Guo et al. 11 examined the association between cold spells and paediatric outpatient visits for asthma, where cold temperatures significantly increased asthma attacks among children. In addition, cross-sectional studies in Korea, 12 Australia 13 and Hong Kong 14 also confirmed an adverse association between a large diurnal temperature variation and the risk of 
SUMMARY AT A GLANCE
We evaluated the effect of temperature variation on an ovalbumin (OVA)-induced mouse model of asthma and investigated the role of transient receptor potential A1 (TRPA1). The results showed that repeated exposure to temperature variation impaired lung function. TRPA1 upregulation exacerbated inflammatory responses, while TRPA1 inhibition presented as a potential therapeutic target. asthma symptoms. A 1 C change in temperature was associated with a 1% increase in asthma-related emergency department visits, 15 confirming the negative impact of temperature variation on asthma.
Cold air, coupled with temperature variations, has been shown to induce contraction of tracheal smooth muscle, decrease pulmonary circulation and lung perfusion and result in airway hyperreactivity, 16 while the mechanism remains incompletely understood. McKemy 17 argued that the transient receptor potential A1 (TRPA1) might be involved in cold air-induced cough in asthma, because an agonist of TRPA1 provoked coughing in healthy volunteers, 18 and it was more significant under inflammatory conditions. 19 The TRPA1 agonist, cinnamaldehyde, activates capsaicinsensitive vagal neurons, causing pulmonary C-fibre discharge, and initiating respiratory irritation reflexes in mice. 20, 21 Caceres et al. 22 found that airway inflammation and airway hyperresponsiveness (AHR) were reduced in TRPA1 −/− asthmatic mice, while treatment with the TRPA1 antagonist HC-030031 significantly reduced cytokines in the airway epithelium. 22 Consequently, it is inferred that TRPA1 may sense temperature and mediate airway inflammatory responses. However, whether and how TRPA1 responds to temperature stimulus in asthma in vivo remains unclear.
To the authors' knowledge, no comprehensive studies have addressed the relationship between temperature variation and asthma, nor the potential molecular mechanism underlying the TRPA1 channel. As an ovalbumin (OVA)-induced mouse model is well recognized as a model of allergic asthma, 23 this study, based on that model, explores whether temperature variations promote airway inflammation. Further, through introducing a TRPA1 blocker, we examined whether the TRPA1 senses temperature stimuli and mediates inflammatory pathways, aiming to identify the potential role of TRPA1 channel in temperature-dependent asthma.
METHODS

Animal model
Specific Pathogen Free (SPF) male BALB/c mice (5-6 weeks) were purchased from Hubei Experimental Animal Center (Wuhan, China). Mice were housed in an environment-controlled room (25 AE 0.5 C and 50-70% relative humidity) for 1 week to acclimatize. All experimental protocols were approved by the Office of Scientific Research Management of Central China Normal University (approval ID: CCNU-IACUC-2016-003).
Experimental design
The experiment was designed to simulate the temperature variations to which people are exposed daily in winter when indoor heating is available. A total of 48 mice were allocated into six groups (eight mice/group) according to designs and treatments: (I) Saline-26 C group; (II) OVA-26 C group; (III) OVA-26 C/18 C group; (IV) OVA-26 C/10 C group; (V) OVA+HC030031-26 C group; and (VI) OVA+HC030031-26 C/10 C group (Fig. S1, Supplementary Information) .
To enable OVA sensitization and challenge and TRPA1 blocking, a 21-day experimental period was designed. On days 1, 4, 7, 10 and 13, mice in groups II-VI were sensitized with OVA (50 μg OVA with 1.75 mg aluminium hydroxide as an adjuvant in a total volume of 300 μL of saline). From day 14 to day 21, all mice in groups II-VI were challenged with an aerosol of 1% OVA (OVA: saline, 1:99 w/v) for 30 min using an ultrasonic nebulizer (Yuyue 402A Type I, Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., Nanjing, China). In addition, mice in groups V and VI were given HC-030031 intraperitoneally (30 mM HC-030031 stock in DMSO and 0.2% Tween 80 in saline) at a dose of 30 mg/kg/per every 5 days from day 1 to day 16.
All mice were fed in the climate chamber (BD-PRX-150A, Hangzhou Jtone Electronic Co.Ltd., Hangzhou, China). For groups I, II and V, the temperature was set at 26 C. For group III, it was set at 26 C for 12 h and 18 C for 12 h. For groups IV and VI, the temperature was set at 26 C for 12 h and 10 C for 12 h. During the experiments, the mice had access to water and food ad libitum.
Serum Ig and BALF cytokines
Mice were sacrificed 24 h after the final OVA challenge. Blood samples were obtained by heart puncture. The blood was kept at room temperature for 30 min and then centrifuged (24 C, 3000 rpm, 15 min). Enzymelinked immunosorbent assay (ELISA) kits for total-IgE (immunoglobulin E; limit of detection 4 ng/mL) and the OVA-specific IgG1 (0.1 mg/mL) were obtained from BlueGene (Shanghai, China). Concentrations were determined in duplicate for each sample.
Ice-cold saline of 1 mL was instilled into the trachea and lung three times, and the entire process was repeated twice to obtain approximately 1.5 mL bronchoalveolar lavage fluid (BALF). Supernatants of the BALF samples were collected after centrifugation (1000 rpm, 4 C, 10 min) and stored (−80 C). The cell pellets were later re-suspended using 500 μL saline, and inflammatory cells were counted using a haematology analyser (MTN-21, China).
BALF supernatants were thawed to room temperature before use. Cytokine levels were determined using commercial ELISA kits from eBioscience (San Diego, CA, USA) according to the manufacturer's instructions. The lowest detection limits for IL-4, IL-6, IL-13 and IL-17 were 4 pg/mL, 15 pg/mL for interferon-gamma (IFN-γ) and 1.0 pg./mL for granulocyte-macrophage colony-stimulating factor(GM-CSF).
Histological analysis
Tissue from the lung biopsies was fixed in 4% formaldehyde and embedded in paraffin. Slices of 3-μm thick were mounted onto slides, and stained with haematoxylin and eosin(HE), Periodic Acid-Schiff (PAS) and Masson's Trichrome (MT). For immunohistochemistry, after dewaxing, rehydration and antigen retrieval, the sections were incubated with 0.3% hydrogen peroxide and blocked by appropriate normal serum. Sections were subsequently incubated overnight at 4 C with monoclonal antibodies: anti-Mast Cell Tryptase (1:100; Abcam, MA, USA) and anti-TRPA1 (1:100, Abcam). The reaction product was visualized by Diaminobenzidine (DAB) complexes. The negative control was obtained by omitting the primary antibody. Sections were washed again, counterstained with haematoxylin, dehydrated, cleared and mounted in DPX (Sigma-Aldrich Corp., St.Louis, MO, USA).
Airway hyperresponsiveness
An identical experimental protocol was repeated for another six groups (8 mice/group, totally 48 mice) to measure lung function using an AniRes 2005 lung function system (Beijing Bestlab High-Tech Co., Ltd., Beijing, China). Mice were anaesthetized with pentobarbital sodium (CAS no. 57-33-0, Sigma-Aldrich) at a dose of 100 mg/kg by intraperitoneal injection. The respiratory rate was pre-set at 90 breaths/min and the ratio of expiration/inspiration at 1.5:1. Methacholine (MCH, Oacetyl-β-methylcholine chloride, Sigma-Aldrich) was injected into the jugular vein with doses of 0.025, 0.05, 0.1 and 0.2 mg/kg successively every 5 min. The inspiratory resistance (Ri), expiratory resistance (Re) and lung dynamic compliance (Cldyn) were recorded using the AniRes2005 software (Beijing Bestlab High-Tech Co., Ltd, Beijing, China). 24 
Statistical analysis
Data in each group were presented as mean AE SD of all mice. An independent sample t-test was used to determine the differences between the six groups. Analysis of variance (ANOVA) with post hoc analysis was employed to test the differences by temperature variable. A P-value of <0.05 was considered statistically significant.
RESULTS
Changes in lung histopathology
Histopathological changes of mice are shown in Figure 1 . Compared to Saline-26 C, there was a remarkable difference in the bronchial epithelium thickness, inward folding and inflammatory cell infiltration around the airways in the OVA-26 C group (HE staining; Fig. 1A -II), which were more obvious in the OVA-26 C/18 C and OVA-26 C/10 C groups (Fig. S2, Supplementary Information) . In addition, the PAS-positive mucus cell staining (Fig. 1B , pale pink colour) and the subepithelial collagen deposition were increased (MT staining; Fig. 1C , blue colour) in the OVA-26 C/10 C group. After TRPA1 blocking, Figure 1A -VI shows less airway wall thickening and folding, and inflammatory cell infiltration in the OVA +HC030031-26 C/10 C group compared to Figure 1A -IV (HE staining in Fig. 1A ). The degree of subepithelial collagen deposition under the lamina propria in Figure 1C -VI was less with MT staining compared to Figure 1C -IV in OVA-26 C/10 C group.
Serum Ig levels
The levels of total-IgE and IgG1 in serum are presented in Figure 2 . Compared to Saline-26 C group, there were significant increases for the OVA-induced groups (P < 0.05). The levels of total-IgE and IgG1 were nearly fourfold and threefold higher, respectively, in the OVA-26
C group compared to Saline-26 C group, and even sevenfold and fourfold higher in the OVA-26 C/10 C group. By contrast, with the administration of HC030031, the levels of both total-IgE and IgG1 were significantly lower in the OVA+HC030031-26 C/10 C group in Figure 2 , compared to the levels of total-IgE and IgG1 in OVA-26 C/10 C group (P < 0.05). Figure 3A , B shows the number of total BALF cells, lymphocytes (Lym), neutrophils (Neu), and eosinophils (Eos) in the six groups. The levels of total BALF cells, Lym, Neu and Eos increased in OVA-26 C and OVA +HC030031-26
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C groups compared to Saline-26 C group, but they were not statistically significant (P > 0.05). However, compared to control Saline-26 C group, significant differences in the levels of total BALF cells, Lym, Neu and Eos were found in the OVA-26 C/18 C and OVA-26 C/10 C groups (P < 0.05), suggesting that repeated exposure to temperature-varying environments with large differences significantly exacerbated asthmatic inflammation. The levels of these inflammatory cell were observed to be significantly reduced (total BALF cells by 25.9%, Lym by 30% and Eos by 29.7%) in the OVA+HC030031-26 C/10 C group, when taking the levels of total BALF cells, Lym, Neu and Eos in OVA-26 C/10 C group as a baseline. Figure 3C , D show the mast cell degranulation staining. There was no tan stain in the lung section of the Saline-26 C group, while the tan colours were deeper in the temperature-changed groups, particularly in the OVA-26 C/10 C group (Fig. 3C) . However, the staining was lightened in the OVA+HC030031-26 C/10 C group. This was further verified by the average optical density assay of mast cell degranulation in Figure 3D .
TRPA1 expression assay
TRPA1 expression was examined by immunohistochemical staining (Fig. 4) . TRPA1 upregulation was observed in the five experimental OVA groups compared to the controlled Saline-26 C (Fig. 4A) , with significant differences in average optical density (P < 0.05) (Fig. 4B ). However, with the pre-administration of HC030031, the degree of staining was ameliorated in the OVA+HC030031-26 C/10 C group compared to OVA-26 C/10 C group. This verified the activation and expression of TRPA1 caused by temperature variation stimulus while HC030031 successfully inhibited the TRPA1 expression.
BALF cytokines and pro-inflammatory factors
The levels of IL-4 and IFN-γ and other pro-inflammatory factors are shown in Table 1 . Significant differences were found for IL-4, IFN-γ, IL-6, IL-13, IL-17 and GM-CSF in the OVA-induced groups compared to the Saline-26 C group (P < 0.05), and in the OVA-26 C/18 C and OVA-26 C/10 C groups compared to the OVA-26 C group (P < 0.05). This showed that repeated exposures to large temperature variations significantly increased the levels of inflammatory factors. However, compared with the levels of IL-4, IL-6, IL-13 and GM-CSF in the OVA-26 C/10 C group in Table 1 , statistical analysis showed that in the OVA+HC030031-26 C/10 C group the levels Temperature variation and asthma of IL-4, IL-6, IL-13 and GM-CSF were significantly inhibited by the administration of HC030031 (P < 0.05), suggesting that the TRPA1 blocking attenuated the asthmalike pathology (Fig. S3, Supplementary Information) . Figure 5 shows the airway responses of mice. Both the Ri and Re increased with an increasing dose of MCH (Fig. 5A,B) , and they were more significant at higher MCH doses. With an MCH dose of 0.1 and 0.2 mg/kg, the Ri and Re showed significant increases in the OVA-26 C/18 C and OVA-26 C/10 C groups (P < 0.05) while they decreased noticeably in the OVA +HC030031-26 C/10 C group (P < 0.05) compared to the Saline-26 C group. The pulmonary compliance was much lower when the temperature changed periodically (Fig. 5C) , indicating that the temperature variations significantly affected the asthmatic airway structures.
DISCUSSION
Although inhalation of cold air is recognized as causing epithelial injury and mucosal inflammation, the regulatory mechanism in vivo is not adequately characterized. Our study shows that repeated exposures to varying temperatures increase the levels of IL-4 and IL-13, along with other pro-inflammatory factors (Table 1) , which are consistent with Davis et al.'s study. 25 In that case, the high levels of IL-4 and IL-13 result in an increase in total-IgE level 26 and temperature variation further promotes the development (Fig. 2A) . Meantime, the increasing levels of IL-17, IL-6 and GM-CSF further enhance the function of IL-4 and IL-13. 27 Moreover, the IgG1, associated with protecting against allergic reactions in mice, 28 was regulated by IL-4 and enhanced by the large temperature variation (Fig. 2B) . The inflammatory responses are directly observed in Figure 3 with inflammatory cell infiltration and mast cell degranulation in the airways. 29 The respiratory resistances and airway remodelling are also exacerbated (Figs 1,5 ), due to thickening of the airway wall, 30 uncoupling of airway contraction as well as excessive contraction of airway smooth muscle. 31 The TRPA1, activated by cold temperatures etc., 32 has been identified in primary sensory afferent nerves and small diameter nociceptive neurons to detect noxious stimuli and mediate inflammatory hyperalgesia and neurogenic inflammation. 33 In this study, we focus primarily on the crucial role of TRPA1 to sense temperature stimuli in vivo and examine TRPA1 function through blocking. Our results demonstrated that when the temperature changed by a large amount (i.e. from 26 C to 10 C, to 26 C periodically), significant increase in inflammation was observed in OVA-challenged mice, while the increase was ameliorated by TRPA1 blockade. This suggests that the TRPA1 might sense large temperature variations and exacerbate temperatureinduced allergic inflammation. TRPA1 blockade following OVA challenge and large environmental temperature fluctuation inhibits inflammatory signalling pathways, and thus attenuates the inflammatory responses, which accords with previous studies. 22, 34 As the activation of TRPA1 would initiate inflammatory signalling pathways, resulting in a Ca 2+ influx, 35 this effect is likely to be at the level of sensory nerves, due to HC030031 inhibiting the Bradykinin (BK)-induced sensory neuron, Ca 2+ flux and vagus nerve depolarization. 36 There is increasing evidence of two TRP channels, that is TRPA1 and Transient Receptor Potential Vanilloid 1 (TRPV1), mediating inflammatory responses. 37, 38 They are distributed widely within the respiratory tract to increase the excitability of C-fibres during airway inflammation. 34 The bronchial C-fibres are thus activated by inflammatory mediators and release various neuropeptides, in particular Substance P (SP) and Calcitonin Gene-related Peptide (CGRP). 39 Wu et al. 40 experimentally revealed that TRPA1 and TRPV1 antagonists reduced the allergen-induced inflammation, pulmonary tissue damage and AHR, via suppression of neuropeptide release including SP and CGRP, which suggests a potential mechanism of temperatureinduced airway inflammation in this study. However, as the TRPV1 was alternatively activated by elevated temperatures (>42 C), 41 one study in mice revealed that TRPV1 was a major mediator of inflammatory thermal hyperalgesia and inflammatory painful hypersensitivity to hot stimuli. 42 Given the current study focuses more on cold temperatures, the significantly negative effect on asthma with TRPA1 upregulation is verified in OVA-26 C/10 C group, which promotes the activation of T helper cell 2 (Th2) cells, the synthesis of cytokines and IgE and tissue remodelling and AHR (Figs 2-5 ). In this case, the administration of HC030031 in OVA+HC030031-26 C/10 C group inhibits the sensory nerve excitability and thus the upregulation of TRPA1 activity, ameliorating the allergic inflammation. In fact, as all major neuronal inflammatory signalling pathways converge on TRPV1 and TRPA1, 34 the co-expression of TRPA1 and TRPV1 is believed to have coupling roles mediating airway inflammation to cold and hot stimuli. Therefore, more studies are needed to identify further the TRPV1-and TRPA1-mediated mechanisms.
Limitations should be noted with respect to the interpretation of this study. The study currently verifies TRPA1 involvement in airway inflammation caused by temperature variations. The question of whether the increasing inflammation is a result of large temperature fluctuations or of the coldest temperatures remains to be explored. As TRPA1 is expressed in subsets of sensory neurons in the central and peripheral systems, 32 whether the TRPA1 channel is directly activated by cold or its activation is an indirect effect needs to be examined.
In conclusion, this study highlights the significant effect of repeated exposure to temperature variations on the aggravation of an existing experimental model of asthma in vivo. The upregulation of TRPA1 mediates inflammatory pathways and exacerbates pulmonary dysfunction, while TRPA1 inhibition attenuates airway injury and asthma-like features. As the TRP channels are highly conserved between animals and human, 43 these results are expected to provide an insight into the role of TRPA1 in temperature variation-invoked human asthma. Further studies are needed to better characterize TRPA1 in airway inflammation, which may be beneficial for the potential protection and treatment of asthmatic populations.
